Treating Drug-Resistant Tuberculosis

Skip to the navigation

Topic Overview

People infected with tuberculosis (TB) bacteria that are antibiotic-resistant have what is called drug-resistant tuberculosis. There are different types of drug-resistant TB.

  • Mono-resistant TB happens when the bacteria don't respond to one first-line drug.
  • Multidrug-resistant TB happens when the bacteria don't respond to at least the two strongest TB drugs (isoniazid and rifampin).
  • Poly-resistant TB happens when the bacteria don't respond to more than one first line drug other than isoniazid and rifampin.
  • Extensively drug-resistant TB happens when the bacteria are resistant to isoniazid, rifampin, and several other medicines used to treat TB. This is rare.

People with drug-resistant tuberculosis need special treatment programs. Treatment usually involves several medicines.

  • The choice of medicines depends on the results of sensitivity testing.
  • It is very important to take every dose of medicine. So directly observed therapy (DOT) usually is done. During DOT, a health professional watches you take every dose of medicine.
  • Treatment is continued until TB bacteria can no longer be found in two sputum samples taken a month apart. This may take 18 months or longer in people with multidrug-resistant TB (MDR-TB).

Some TB bacteria have become resistant to all of the antibiotics that are commonly used to treat TB. This is sometimes called totally resistant tuberculosis (TDR-TB).footnote 1 A TB infection of this type is very difficult to treat.

Related Information

References

Citations

  1. Cegielski P, et al. (2012). Challenges and controversies in defining totally drug-resistant tuberculosis. Emerging Infectious Diseases [Internet], November. Available online: http://wwwnc.cdc.gov/eid/article/18/11/12-0526_article.htm.

Credits

ByHealthwise Staff
Primary Medical ReviewerE. Gregory Thompson, MD - Internal Medicine
Adam Husney, MD - Family Medicine
Specialist Medical ReviewerR. Steven Tharratt, MD, MPVM, FACP, FCCP - Pulmonology, Critical Care Medicine, Medical Toxicology
W. David Colby IV, MSc, MD, FRCPC - Infectious Disease

Current as ofNovember 22, 2017